Stock Track | Abbott Laboratories Soars 9.67% Intraday on Strong Q2 Earnings Beat and Raised 2026 Profit Forecast

Stock Track

Jul 16

Abbott Laboratories' stock soared 9.67% intraday on Thursday, following the release of its second-quarter 2026 financial results.

The healthcare company reported adjusted earnings per share of $1.31, beating the consensus estimate of $1.28, while revenue of $12.59 billion also exceeded expectations. Furthermore, Abbott raised its full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60, up from its previous forecast of $5.38 to $5.58.

The strong performance was driven by robust growth in the company's diagnostics and medical devices segments. The diagnostics business saw significant expansion, particularly in cancer diagnostics following the acquisition of Exact Sciences, while heart devices and diabetes care products also showed strong demand that is expected to continue through the second half of the year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1134876413"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1134876413\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1134876413?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134876413","market":"us","top_or_hot":-1,"title":"Stock Track | Abbott Laboratories Soars 9.67% Intraday on Strong Q2 Earnings Beat and Raised 2026 Profit Forecast","media":"Stock Track","content":"<p>Abbott Laboratories' stock soared 9.67% intraday on Thursday, following the release of its second-quarter 2026 financial results.</p><p>The healthcare company reported adjusted earnings per share of $1.31, beating the consensus estimate of $1.28, while revenue of $12.59 billion also exceeded expectations. Furthermore, Abbott raised its full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60, up from its previous forecast of $5.38 to $5.58.</p><p>The strong performance was driven by robust growth in the company's diagnostics and medical devices segments. The diagnostics business saw significant expansion, particularly in cancer diagnostics following the acquisition of Exact Sciences, while heart devices and diabetes care products also showed strong demand that is expected to continue through the second half of the year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Abbott Laboratories Soars 9.67% Intraday on Strong Q2 Earnings Beat and Raised 2026 Profit Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Abbott Laboratories Soars 9.67% Intraday on Strong Q2 Earnings Beat and Raised 2026 Profit Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-16 21:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Abbott Laboratories' stock soared 9.67% intraday on Thursday, following the release of its second-quarter 2026 financial results.</p><p>The healthcare company reported adjusted earnings per share of $1.31, beating the consensus estimate of $1.28, while revenue of $12.59 billion also exceeded expectations. Furthermore, Abbott raised its full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60, up from its previous forecast of $5.38 to $5.58.</p><p>The strong performance was driven by robust growth in the company's diagnostics and medical devices segments. The diagnostics business saw significant expansion, particularly in cancer diagnostics following the acquisition of Exact Sciences, while heart devices and diabetes care products also showed strong demand that is expected to continue through the second half of the year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABT","symbol_name":"雅培","start_time":0,"source_url":"","article_id":"1134876413","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134876413","pubTimestamp":1784208979,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Abbott Laboratories' stock soared 9.67% intraday on Thursday, following the release of its second-quarter 2026 financial results.The healthcare company reported adjusted earnings per share of $1.31,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABT":"雅培"},"translate_title":"股票跟踪 | 雅培实验室第二季度盈利强劲，盘中飙升 9.67%，并上调了 2026 年利润预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":1},"content_text":"Abbott Laboratories' stock soared 9.67% intraday on Thursday, following the release of its second-quarter 2026 financial results.The healthcare company reported adjusted earnings per share of $1.31, beating the consensus estimate of $1.28, while revenue of $12.59 billion also exceeded expectations. Furthermore, Abbott raised its full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60, up from its previous forecast of $5.38 to $5.58.The strong performance was driven by robust growth in the company's diagnostics and medical devices segments. The diagnostics business saw significant expansion, particularly in cancer diagnostics following the acquisition of Exact Sciences, while heart devices and diabetes care products also showed strong demand that is expected to continue through the second half of the year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}